Paper Details

  1. Home
  2. Paper Details

[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].

Author: KasjanG R

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Mirabegron, a beta-3 adrenergic agonist, is a new oral therapy for overactive bladder (OAB). It is approved for use in Europe and North America and is effective in treating urge urinary incontinence, urgency, and urinary frequency.
Paper Details　
Original Abstract of the Article :
Mirabegron is the first drug in a new class of oral therapy for overactive bladder (OAB). It is a beta-3 adrenergic agonist, a class of drugs for the first time used for the treatment of urination disorders. Recently, following many years of rigorous multicenter randomized trials mirabegron has been...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26665779

データ提供：米国国立医学図書館（NLM）

Mirabegron: A New Oasis for Overactive Bladder Treatment

Overactive bladder (OAB) is a common condition that can significantly impact quality of life. This research delves into the world of mirabegron, a novel medication for OAB, offering a fresh perspective on managing this often debilitating condition. Imagine a camel seeking relief from a scorching desert, finding a refreshing oasis—mirabegron could be a similar source of relief for individuals with OAB. This study explores the potential of mirabegron as a safe and effective treatment option, providing a new path forward for managing this common condition.

A New Era for OAB Treatment

Mirabegron is the first drug in a new class of oral therapy for OAB. It acts as a beta-3 adrenergic agonist, offering a unique approach to managing OAB symptoms. The researchers found that mirabegron has a good safety profile and causes no side effects typical of anticholinergics, making it a potentially valuable alternative for patients seeking relief from OAB.

Finding Relief from OAB

This research provides hope for individuals struggling with OAB. The development of new and effective treatments is essential for improving the lives of those affected by this condition. If you experience OAB symptoms, consult with a healthcare professional to discuss treatment options and find the best path towards relief.

Dr. Camel's Conclusion

This research explores the exciting potential of mirabegron as a new and effective treatment option for OAB. Its unique mechanism of action and favorable safety profile offer a promising path forward for managing this common condition.

Date :
  1. Date Completed 2015-12-29
  2. Date Revised 2015-12-14
Further Info :

Pubmed ID

26665779

DOI: Digital Object Identifier

26665779

Related Literature

Article Analysis
・Side Effects of mirabegron
SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.